Vaccine Choice Canada

Your Child. Your Future. Your Choice.

Donate Button
  • About Vaccines
    • Vaccination: Basic Concerns
      • Children’s Health in Decline
      • Contraindications to Vaccination
      • Parent’s Guide to Vaccination
      • Adverse Events – Unreported
      • Disease Trends
    • General Issues
      • Informed Consent – Mature Minor – Ethics
      • Politics of Vaccination
      • Healthcare Worker & Student Vaccines
      • Herd Immunity
      • Doctors Speak
      • Parents Speak
      • Reports
    • Specific Vaccines
    • Vaccine Ingredients
  • Health Risks
  • Science
  • Exemptions
    • Legal Exemption Forms
    • Canadian Medical Law
    • Ontario Daycare Exemptions
    • Immunization Not Mandatory in Canada
    • Threats to Exemptions
    • Take Action / Events
  • Personal Stories
  • Alternatives
    • Alternatives – Specific Infections
  • Articles
  • Resources
    • Child Health Links
    • Pro-vaccine websites
    • Video & Audio
  • Home
  • About VCC
    • Policy Statement on Vaccination
    • Who We Are & What We Do
    • VCC History
    • Privacy Policy
    • Disclaimer
  • Join
  • Report a Reaction
  • Bookstore
  • Contact
  • Member’s Area
    • Journal Archive
  • Site Map
  • Media
You are here: Home / Disease Trends / Outbreak of Meningococcal Disease Due to a Novel Serogroup C

Outbreak of Meningococcal Disease Due to a Novel Serogroup C

January 18, 2001 By Vaccine Choice Canada

Alberta, Canada

By Dr. Marcia Johnson
January 18, 2001
Click Here To Visit ProMED-mail
(A Program for Monitoring Emerging Diseases by the International Society for Infectious Diseases)

Capital Health Authority (CHA) serves a population of 827 500 in Edmonton, Alberta and surrounding counties. The region has experienced significantly increased rates of invasive meningococcal infection since Dec 1999 associated with a novel serogroup C clone.

The usual incidence of invasive meningococcal disease in the region is 0.5 to 1.5 /100 000 annually. Between Dec 1999 and Dec 2000 inclusive 49 cases of invasive meningococcal disease occurred in CHA (47 in 2000). All cases have been sporadic affecting all parts of the region (although 2 cases in Dec 2000 attended the same rave-like event). Routine public health follow-up including contact tracing and prophylactic antibiotics has occurred with each case. The age groups most affected were 0-4, 15-19 and 20-24 years with rates of 21.6, 27.3 and 10.6 per 100 000 respectively in 2000.

The outbreak was declared in Feb 2000 when the rate in the 15-19 year group reached 10/100 000 in less than 3 months. A mass immunization campaign in Edmonton and surrounding counties using quadrivalent vaccine was undertaken with the cooperation of Alberta Health & Wellness with 168 000 children aged 2 to 19 immunized over a 2-week period in Feb 2000 (an 80% coverage rate).

Cases continued to occur through the spring and summer in all age groups but primarily in those 19 years or less. Vaccine effectiveness rate was 92% between Feb and Oct with 2 cases in immunized children and 6 cases in the population eligible for immunization but unimmunized. The case occurrence accelerated in the Fall of 2000, resulting in a rate of 10.6/100 000 in the 20-24 year age group. In Oct 2000 quadrivalent vaccine was again offered to unimmunized 2-19 year olds and the vaccine campaign was expanded to all 20-24 year olds. A further 60 000 young people were immunized with resulting in a coverage rate of 87% of 2 to 25 year olds.

The Microbiology & Public Health Laboratory (M&PHL) of Alberta (Edmonton) identified a novel strain of _Neisseria meningitidis_ serogroup C through DNA characterization of involved strains by Restriction Fragment Length Polymorphisms using Pulsed Field Gel Electrophoresis (PFGE) as the causative organism in 92.9 percent (39/42) of the recovered serogroup C isolates. PFGE was performed within days of specimen isolation. The lab examined the previous 4 years of meningococcal isolates in Alberta and did not find a similar strain. Isolates from other jurisdictions are currently being tested with no similar isolate being identified to date.

In summary, CHA has experienced an outbreak of meningococcal disease caused by a new serogroup C clone previously unrecognized in this province. The demonstration of the disease consequences of a new clone in a community combined with timely laboratory characterization of different serogroup C clones may prove to be ground breaking in the future management of meningococcal disease.

Marcia M. Johnson, MD, MHSc, FRCPC
Deputy Medical Officer of Health
Capital Health Authority
Edmonton, Alberta, Canada
mailto:MJohnson@cha.ab.ca

[Our thanks to Dr. Johnson for this very rapid and thorough reply. According to the original ProMED-mail posting, this outbreak was described as a community-wide person-to-person outbreak and not institutional-based. In the USA, living in college dormitories has been associated with higher risk of disease so that recommendations now include meningococcal vaccination prior to college entry. One wonders if the 20-24 year old population affected by this outbreak were students and would have classified as eligible for vaccination in the USA within the 4 to 5 year protective range of the vaccine. Some questions that remain are: Is the outbreak still ongoing? and, have other provinces in Canada seen the introduction of this novel type of Group C meningococcus? – Mod.MPP]

Share this:

Filed Under: Disease Trends, Meningococcal Disease Vaccine Tagged With: Meningococcal Disease

Articles by Category

  • About Vaccines
    (179)
    • Adverse Events
      (106)
    • Compensation
      (6)
    • Contraindications
      (1)
    • Herd Immunity
      (11)
    • Informed Consent – Mature Minor – Ethics
      (80)
    • Reports
      (13)
  • Disease Trends
    (27)
  • Doctors Speak
    (55)
  • Exemptions
    (171)
    • Take Action
      (111)
    • Threats to Exemptions
      (153)
  • Health Risks
    (147)
    • Anaphylaxis, Allergies, and Asthma
      (26)
    • Autism
      (55)
    • Brain and Neurological Injuries
      (37)
    • Cancer
      (3)
    • Decline in Children's Health
      (26)
    • Gulf War Syndrome
      (4)
    • Infertility
      (1)
    • Obesity and Diabetes
      (4)
    • Pregnancy – Risks to the Foetus
      (5)
    • SIDS-SBS
      (12)
  • Media
    (83)
  • Parents Speak
    (32)
  • Personal Stories
    (28)
  • Politics of Vaccination
    (40)
  • Resources
    (61)
    • Books & Periodicals
      (1)
    • PDF files
      (3)
    • Videos
      (0)
  • Specific Vaccines
    (229)
    • Chickenpox and Shingles Vaccines
      (12)
    • COVID-19 Vaccine
      (11)
    • Diphtheria, Tetanus, Pertussis, and Hib Vaccine
      (38)
    • Healthcare Worker & Student Vaccines
      (15)
    • Hepatitis-B Vaccine
      (20)
    • HPV Vaccine
      (19)
    • Influenza Vaccine
      (46)
    • Measles, Mumps, & Rubella Vaccine
      (47)
    • Meningococcal Disease Vaccine
      (9)
    • Pet Vaccines
      (1)
    • Pneumococcal Disease Vaccine
      (4)
    • Polio Vaccine
      (13)
    • Rotavirus Vaccine
      (1)
    • Smallpox Vaccine
      (4)
    • Travel Vaccines
      (1)
  • Vaccine Alternatives
    (13)
    • Vaccine Alternatives – General
      (7)
    • Vaccine Alternatives – Specific Infections
      (6)
  • Vaccine Ingredients
    (69)
    • Aluminum
      (23)
    • Biological Ingredients
      (15)
    • Chemical Ingredients
      (15)
    • Food Allergens
      (4)
    • Mercury
      (24)
    • Oil-based Adjuvants
      (11)

Join Vaccine Choice Canada

To support our educational and outreach work , please join Vaccine Choice Canada today. Sign Me Up!

Log In


Lost your password?

About Vaccine Choice Canada

Vaccine Choice Canada is a volunteer run, federally registered … read more

Our Mission

Vaccine Choice Canada (formerly VRAN) continues the work of … more

Disclaimer

The contents of this website are for informational purposes … more

Vaccine Choice Canada logo

Find More on

  • Decline in Children's Health
    (26)
  • Doctors Speak
    (55)
  • Exemptions
    (130)
  • Health Risks
    (39)
  • Parents Speak
    (32)
  • Personal Stories
    (28)
  • Resources
    (60)
  • Specific Vaccines
    (92)
  • Vaccine Alternatives
    (8)
  • Vaccine Ingredients
    (22)

Personal Stories

Susan’s Flu Vaccine Reaction

In 2013, I contracted the H1N1 strain of flu.  I was deathly … [Read More...]

My Journey with Vaccine Awareness and a closer look at Vaxxed vs. Unvaxxed

I was born in the mid 1980’s and was fully vaccinated as a … [Read More...]

A story of my grandson’s visit, discovery of his autism, and how he recovered

By Shanna Mi    November 2019 It was a glorious late … [Read More...]

Laura’s Story

July 2002 Today is my daughter's sweet 16th birthday but … [Read More...]

More Personal Stories

Featured Articles

Open Letter to Dr. Bonnie Henry from BC Physician re: Moderna Vaccine Reactions

Dr. Charles D. Hoffe, BSc, MB, BCh, LMCC Lytton Medical … [Read More...]

News Nuggets April 12, 2021 – Top News Items

Compiled by Edda West FEATURES Perspectives on the … [Read More...]

COVID-19

COVID-19 Resources (printable) & Take Action – Letter … [Read More...]

News Nuggets April 2, 2021 – Top News Items

Compiled by Edda West FEATURES Naomi Wolf speaks to … [Read More...]

More News Articles

Copyright © 2021 Vaccine Choice Canada